| Literature DB >> 27387641 |
Emma Scott1, Diana Learoyd1,2, Roderick J Clifton-Bligh1,2,3.
Abstract
The treatment of papillary thyroid cancer is now based on individual patient risk and response to therapies. Molecular techniques are increasingly being used to risk stratify and to guide therapeutic decisions. There have been advances in the treatment of local disease through surgery or radioiodine. Directed techniques can target metastatic disease including bisphosphonates, radiofrequency ablation or radiotherapy. Systemic therapies such as tyrosine kinase inhibitors show great promise although such treatment must be individualized. Future therapies will target treating radioiodine refractory disease.Entities:
Keywords: BRAF; TERT; papillary thyroid cancer; radioactive iodine; tyrosine kinase inhibitors
Mesh:
Substances:
Year: 2016 PMID: 27387641 DOI: 10.2217/fon-2016-0171
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404